US2020114000A1PendingUtilityA1

Combination treatment of cd38-expressing tumors

73
Assignee: GENMAB ASPriority: Sep 26, 2006Filed: Sep 12, 2019Published: Apr 16, 2020
Est. expirySep 26, 2026(~0.2 yrs left)· nominal 20-yr term from priority
Inventors:Jan Van De WinkelPaul ParrenYvo GrausJudith OprinsMichel De WeersMartine Van VugtOle BaadsgaardSteen Lisby
A61K 39/39558A61K 45/06A61K 2039/505A61P 35/00A61K 39/3955A61K 31/573A61K 31/4439C07K 16/2896A61K 31/69C07K 2317/34A61K 31/198A61P 19/02
73
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to novel method for the treatment of cancer using a combination therapy comprising an antibody that binds CD38, a corticosteroid and a non-corticosteroid chemotherapeutic agent.

Claims

exact text as granted — not AI-modified
1 - 73 . (canceled) 
     
     
         74 . A method for treating rheumatoid arthritis in a subject comprising administering to the subject an antibody which binds to CD38 and comprises light and heavy chain variable region CDRs set forth in SEQ ID NOs: 13, 14, and 15 and SEQ ID NOs: 18, 19, and 20, respectively. 
     
     
         75 . A method for treating rheumatoid arthritis in a subject comprising administering to the subject an antibody which binds to CD38 and comprises light and heavy chain variable region sequences which are at least 90% identical to SEQ ID NOs: 12 and 17, respectively. 
     
     
         76 . The method of  claim 74 , wherein the antibody is internalized by CD38 expressing cells. 
     
     
         77 . The method of  claim 74 , wherein said antibody does not induce release of significant IL-6 by human monocytes or peripheral blood mononuclear cells. 
     
     
         78 . The method of  claim 74 , wherein said antibody does not induce release of detectable IFN-γ by human T cells or peripheral blood mononuclear cells. 
     
     
         79 . The method of  claim 74 , wherein the antibody is a monoclonal antibody. 
     
     
         80 . The method of  claim 74 , wherein the antibody is a human monoclonal antibody. 
     
     
         81 . The method of  claim 74 , wherein the antibody is a full length IgG1, IgG2, IgG3, IgG4, IgD, IgA, IgE, or IgM antibody. 
     
     
         82 . The method of  claim 74 , wherein the antibody is an antibody fragment or a single-chain antibody. 
     
     
         83 . The method of  claim 74 , wherein the antibody is conjugated to a cytotoxic agent, a radioisotope, or a drug. 
     
     
         84 . The method of  claim 74 , further comprising administering at least one corticosteroid. 
     
     
         85 . The method of  claim 74 , further comprising administering an anti-inflammatory agent. 
     
     
         86 . The method of  claim 74 , further comprising administering an immunosuppressive agent. 
     
     
         87 . The method of  claim 74 , further comprising administering an immunomodulatory agent. 
     
     
         88 . A method for treating multiple myeloma in a subject comprising administering to the subject an antibody which binds to CD38 and comprises light and heavy chain variable region CDRs set forth in SEQ ID NOs: 13, 14, and 15 and SEQ ID NOs: 18, 19, and 20, respectively.

Join the waitlist — get patent alerts

Track US2020114000A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.